CJMB Callan JMB: Company Value to Revenue

Official company branding of Callan JMB Corp (CJMB)

Regular supplies of orthopedic consumables ensure a steady cash flow for Callan JMB Inc (CJMB), while business success depends on government budgets and the growth rate of minimally invasive surgeries. This enterprise value-to-revenue chart captures market expectations, with the metric currently standing at 995.82. Specialized instrumentation supports the current moderate growth, while the potential for expanding product lines is only beginning to take shape.

Callan JMB Inc. (CJMB): Enterprise Value-to-Revenue Ratio from 11/23/2025 to 11/20/2026

CJMB (Callan JMB Inc.): analytical breakdowns and indicator data

- current quotes and average value forecast:
- company stock capitalization data:
Fundamental company valuation:Callan JMB Inc
Manufactured products of Callan JMB

Stable government contracts at Callan JMB Inc (CJMB) ensure a predictable cash flow, making changes in the EV/Sales ratio a reliable tool for monitoring the business's market value. This metric compares the total enterprise value (market capitalization plus net debt) with annual revenue, allowing investors to assess the asset's real value regardless of debt load and determine the degree to which shares are overbought relative to operational efficiency.

Competitor analysis for Callan JMB Inc

ISRG - EV/Sales Multiple|DHR: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple BD (BDX)|Enterprise Value-to-Revenue Ratio STERIS plc|Company Value to Revenue Ratio WST (West Pharmaceutical Services)|Company Value to Revenue BAX (Baxter Corp)|Masimo - Company Value to Revenue Ratio|Stevanato Group S.p.A. - Company Value to Revenue|Total Company Value-to-Revenue Ratio Teleflex Inc (TFX)|MMSI - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio Envista Holdings Corp NVST|ICUI: EV/Sales Multiple|Company Value to Revenue Ratio XRAY|LMAT (LeMaitre Corp) - EV/Sales Multiple|ATRC (AtriCure Inc) - Enterprise Value-to-Revenue Coefficient|EV/Sales Multiple STAA|NAGE (ChromaDex Corp) - Business Value to Revenue|ZimVie Inc. - Company Value to Revenue|Total Company Value-to-Revenue Ratio angiodynamics.com (ANGO)|CERS - Enterprise Value-to-Revenue Ratio|TKNO - EV/Sales Multiple|Monogram Technologies Inc (MGRM) - Enterprise Value-to-Revenue Ratio|STSS - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio InfuSystem Holdings, Inc.|Enterprise Value-to-Revenue Multiple Utah Medical Products UTMD|EV/Sales Multiple KRMD|Total Company Value-to-Revenue Ratio Nyxoah, S.A.|Microbot Medical Inc - Company Value to Revenue|Total Company Value-to-Revenue Ratio Pro-Dex Inc. (PDEX)|Zentek - EV/Sales Multiple|Elutia (ELUT) - Company Value to Revenue|Milestone Scientific Inc (MLSS) - Enterprise Value-to-Revenue Ratio|NXGL - Total Company Value-to-Revenue Ratio|Company Value to Revenue RVP|Harvard Bioscience, Inc. (HBIO) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple FEMY|EV/Sales Multiple Meihua Medical Technologies (MHUA)|EV/Sales Multiple POAI (Predictive Oncology)|EV/Sales Multiple Atrion Corp ATRI|NeuroMetrix Corporation - EV/Sales Multiple